Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance
- PMID: 11897603
- PMCID: PMC127112
- DOI: 10.1128/AAC.46.4.1119-1121.2002
Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance
Abstract
The in vitro activity of BMS-284756 against 602 Staphylococcus aureus isolates, including 152 that were both methicillin and ciprofloxacin resistant (MIC > or = 4 microg/ml), was determined. For ciprofloxacin-susceptible and nonsusceptible isolates, the MICs at which 50% of organisms were inhibited were 0.015 and 2 microg/ml and the MICs at which 90% of organisms were inhibited were 0.03 and 4 microg/ml, respectively.
Figures
Similar articles
-
In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.Antimicrob Agents Chemother. 2002 Jun;46(6):1651-7. doi: 10.1128/AAC.46.6.1651-1657.2002. Antimicrob Agents Chemother. 2002. PMID: 12019071 Free PMC article.
-
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.Antimicrob Agents Chemother. 2002 Nov;46(11):3370-80. doi: 10.1128/AAC.46.11.3370-3380.2002. Antimicrob Agents Chemother. 2002. PMID: 12384338 Free PMC article.
-
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.Antimicrob Agents Chemother. 1999 Aug;43(8):1845-55. doi: 10.1128/AAC.43.8.1845. Antimicrob Agents Chemother. 1999. PMID: 10428901 Free PMC article.
-
Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.Molecules. 2021 Nov 25;26(23):7153. doi: 10.3390/molecules26237153. Molecules. 2021. PMID: 34885734 Free PMC article. Review.
-
Fluoroquinolones: Neurological Complications and Side Effects in Clinical Practice.Cureus. 2024 Feb 20;16(2):e54565. doi: 10.7759/cureus.54565. eCollection 2024 Feb. Cureus. 2024. PMID: 38516474 Free PMC article. Review.
Cited by
-
Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from 1986 to 2001.Antimicrob Agents Chemother. 2004 Apr;48(4):1361-4. doi: 10.1128/AAC.48.4.1361-1364.2004. Antimicrob Agents Chemother. 2004. PMID: 15047544 Free PMC article.
-
Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.Antimicrob Agents Chemother. 2005 Jun;49(6):2189-99. doi: 10.1128/AAC.49.6.2189-2199.2005. Antimicrob Agents Chemother. 2005. PMID: 15917512 Free PMC article.
-
In vitro antibacterial activity and pharmacodynamics of new quinolones.Eur J Clin Microbiol Infect Dis. 2003 Apr;22(4):203-21. doi: 10.1007/s10096-003-0907-5. Epub 2003 Apr 1. Eur J Clin Microbiol Infect Dis. 2003. PMID: 12687416 Review.
-
The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.Antimicrob Agents Chemother. 2006 Nov;50(11):3568-79. doi: 10.1128/AAC.00641-06. Epub 2006 Aug 28. Antimicrob Agents Chemother. 2006. PMID: 16940059 Free PMC article.
-
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.Antimicrob Agents Chemother. 2007 Apr;51(4):1259-67. doi: 10.1128/AAC.01315-06. Epub 2007 Jan 22. Antimicrob Agents Chemother. 2007. PMID: 17242152 Free PMC article.
References
-
- Chen, D. K., A. McGeer, J. C. de Azavedo, D. E. Low, et al. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239. - PubMed
-
- Gootz, T. D., R. P. Zaniewski, S. L. Haskell, F. S. Kaczmarek, and A. E. Maurice. 1999. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1845-1855. - PMC - PubMed
-
- Hooper, D. C. 1999. Mechanisms of fluoroquinolone resistance. Drug Resist. Update 2:38-55. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources